(Adnkronos) - “È importante sottolineare come l’ipoparatiroidismo sia una malattia nota, ma poco conosciuta. Vorremmo portare l'attenzione sui bisogni che i pazienti hanno rispetto a questa malattia” in attesa che sia resa disponibile una terapia efficace. Lo ha detto Thomas Carlo Maria Topini, general manager Ascendis Pharma Italia, al media tutorial ‘Ipoparatiroidismo: inquadramento epidemiologico e clinico, nuove prospettive di trattamento e burden della patologia’, che si è svolto a Milano.
Category
🗞
NewsTranscript
00:00It is important to underline how lipoparathyroidism is a well-known disease, but little known,
00:12and we would like to draw attention to the needs that patients have with respect to lipoparathyroidism.
00:20Ascendis was born in 2007, focusing on the development of drugs for endocrinological rare diseases.
00:25Currently, the developed company has had the authorization of two drugs from the European Commission,
00:31and in Italy we have had the privilege and the good fortune to have three centers involved,
00:36both in the study of phase 2 and in the study of phase 3,
00:38in terms of the development of replacement therapy for lipoparathyroidism.
00:42So we are committed and we want to ensure that patients in Italy have access to a therapy that could revolutionize their lives.